I am/have/had
I am looking for
Advanced Filters
Found 1 clinical trials
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.
macitentan
patent ductus arteriosus
atrial septal defect
septal defect
left ventricular end-diastolic pressure
- 0 views
- 19 Feb, 2024
- 211 locations